A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
A phase 2 trial of TRK-950 and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Toray Industries, Inc, now recruiting.
Overview
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer is a phase 2 interventional study registered as NCT06038578 by Toray Industries, Inc, with 146 participants planned, started 2023-10-04 and due to reach its primary completion in 2026-06-30. Interventions recorded: TRK-950, Ramucirumab and Paclitaxel.
Similar pages
not linked directly; found by shared links- TrialSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialCinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialTherapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.